Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 16/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619467 | 0.93 | PTGER1 (0.51) | PTGER1CYP2C9LRRK2SRPK3 | |
| SCHEMBL5620350 | 0.93 | PTGER1 (0.59) | PTGER1CYP2C9 | |
| SCHEMBL5621004 | 0.92 | PTGER1 (0.58) | PTGER1CYP2C9 | |
| SCHEMBL5620443 | 0.92 | PTGER1 (0.48) | PTGER1CYP2C9LRRK2SRPK3 | |
| SCHEMBL5621229 | 0.91 | PTGER1 (0.53) | PTGER1CYP2C9LRRK2SRPK3 | |
| SCHEMBL5620990 | 0.91 | PTGER1 (0.47) | PTGER1CYP2C9LRRK2SRPK3 | |
| SCHEMBL5620974 | 0.89 | PTGER1 (0.51) | PTGER1CYP2C9LRRK2 | |
| SCHEMBL5620722 | 0.89 | PTGER1 (0.50) | PTGER1CYP2C9 | |
| SCHEMBL5621585 | 0.89 | PTGER1 (0.56) | PTGER1CYP2C9 | |
| SCHEMBL5621313 | 0.88 | PTGER1 (0.48) | PTGER1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| EP-1492757-A1 | (2-((2-ALKOXY)-PHENYL)-CYCLOPENT-1-ENYL) AROMATIC CARBO- AND HETEROCYCLIC CARBOXYLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084917-A1 | (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | PTGER1 323/4885CYP2C9 1/4885LRRK2 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.